Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
67%(6 trials)

Phase Distribution

Ph phase_4
5
56%
Ph not_applicable
1
11%
Ph phase_2
1
11%
Ph phase_3
2
22%

Phase Distribution

0

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
5(55.6%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (11.1%)
Phase 32 (22.2%)
Phase 45 (55.6%)
N/A1 (11.1%)

Trials by Status

completed9100%

Recent Activity

Clinical Trials (9)

Showing 9 of 9 trials
NCT02175342Phase 2

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00239447Phase 3

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Completed
NCT03474081Phase 4

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03478696Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT03478683Phase 4

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02596009Phase 4

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Completed
NCT02184624Phase 4

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

Completed
NCT02331940Not Applicable

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

Completed
NCT00281567Phase 3

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
9